CUTISS AG, a Swiss pioneering life sciences company specializing in skin regenerative medicine and tissue engineering, announced the first closing of CHF 25 million in its Series C funding round. To date, CUTISS has raised a total of CHF 92 million from private investors, family offices, and public bodies.
